Dr. Wenyan (David) Shen is a well-recognized expert in the antibody, therapeutic protein, and biosimilar field with a proven record of advancing pipelines from discovery to clinical and regulatory approval in both US FDA and EU EMA. As an executive leading research and process development teams in top biotech and big pharma companies, he brings strong interpersonal skills, extensive experience in building collaborative relationships both inside and outside the organization, and success in working in a matrix environment. Innovatively blending the scientific and industrial vision, he brings a proven history of discovering new technologies (more 20 patents or applications and more than 30 peer reviewed papers) with strong industrial application potential.
David serves as Board member and Chairman of Scientific Advisory Board (SAB) for Elpiscience Biopharmaceuticals, a startup company in Shanghai focused on Immuno-Oncology. He is also Senior Vice President, Head of Biologics Research and CMC at NGM Biopharmaceuticals, where David leads Discovery Biologics, Bioanalytical, Process Development and CMC to advance six biologics into clinical stage, including one in phase II clinical trial for liver disease, NASH.
Prior to NGMBio, David was VP, Global Head of Biologics at TEVA Pharmaceuticals, where he set the strategy for Biosimilars, Biobetters and innovative biologics including their pipeline portfolio. In this capacity, he oversaw research, process development, bioassay Center of Excellence (including but not limited to functional assays, immunoassays, potency assays, antibody neutralization assays), and CMC up to phase II clinical materials. The overall staff in his organization was more than 180 and were located in US, Israel, Germany, and Lithuania. In addition, he was Managing Director of Teva-Lonza Joint Venture (TL Biopharmaceuticals) that focused on biosimilar monoclonal antibodies. In his capacity, David’s team successfully advanced many biologics into late stage clinical trials including tbo-filgrastim approval by FDA as well as lipegfilgrastim and biosimilar follitropin alfa pproved by EMA.
David also worked with Merck serving as Executive Director of Biologics Research and GlycoFi overseeing two research sites with more than 100 staff supporting all 7 therapeutic areas across all research labs. His department worked on innovative therapeutic antibody, protein based drug and follow-on biologics (biosimilars and biobetters). David led his leadership team to develop a clear strategy to position Merck Biologics in the right direction for growth through balancing their portfolio with both innovative and follow-on biologics and championing for corporate partnerships to further balance the Biologics Portfolio.
His professional career started at Amgen where David eventually became Director and Head of Protein Science Department at the San Francisco research facility and led a group working on therapeutic antibody, protein based drug discovery for oncology, inflammation, metabolic disorders, and neurosciences. Before moving to San Francisco, he was a group leader for antibody engineering, where they played key roles for more than 8 antibodies currently in early and late stage clinical trials, including denosumab and evolocumab. His group developed a novel Mammalian Antibody Display technology for antibody discovery/selection, which for the first time allows functional display of full length IgG on mammalian cell surface. While working in Amgen David initiated a process for a set of selection criteria for antibody Manufacturability Assessment, which was later implemented and now became a critical document for lead antibody selection.
David graduated from East China University of Science and Technology in Shanghai, China. He then moved to Toronto, Canada on a prestigious government scholarship to pursue his graduate studies. David received his PhD from University of Toronto and went on to finish his Post-doctoral training in the Whitehead Institute, Massachusetts Institute of Technology in Cambridge, Massachusetts before joining Amgen.
Dr. Greenberg is a professor of Medicine and Immunology at the University of Washington, and head of the Program in Immunology at the Fred Hutchinson Cancer Research Center. His research has focused on elucidating fundamental principles of T cell and tumor interactions, developing cellular and molecular approaches to manipulate T cell immunity, and translating insights from the laboratory to treatment of cancer patients with an emphasis on adoptive therapy with genetically engineered T cells. He has received multiple professional awards, is on the scientific advisory boards of several comprehensive cancer centers and biotech companies, and is a scientific founder of Juno Therapeutics. He currently is a member of several AACR advisory committees and is an Editor-in-Chief of Cancer Immunology Research.
Thomas Gajewski, MD, PhD is Professor in the Departments of Pathology and Medicine. He oversees the melanoma oncology clinic, is Leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center, and directs the Human Immunologic Monitoring core facility.
His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. He also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials.
Dr. Gajewski has published more than 200 papers on these subjects, has served on numerous NIH grant review panels, is an editor for Cancer Research and Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past president of the Society for Immunotherapy of Cancer. He was recently awarded the first American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy.
As his laboratory work leads to new potential immunotherapies for cancer, Dr. Gajewski is involved with several early biotech companies. He scientific co-founder of Jounce Therapeutics, and has licensing arrangements with Aduro Biotech and Evelo, a new company focused on the microbiome and cancer.
Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Dr. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.
Dr. Kuchroo came to the United States in 1985, as a Fogarty International Fellow at The National Institutes of Health, Bethesda, MD for one year, before joining the department of pathology at Harvard Medical School, as a research fellow. Later, he joined the Center for Neurologic Diseases at Brigham and Women’s Hospital as a junior faculty member in 1992.He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research Prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly Lecturer in 2014, and obtained a Nobel Laureate Peter Doherty Lecture/Prize in 2014.
Dr. Kuchroo has 25 patents and has founded 5 different biotech companies including, CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including: Biocon, Syngene, Pfizer, Novartis and Glaxo-Smith-Klein (GSK).